Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: [email protected]
The FDA has accepted and granted priority review to the biologics license application seeking the approval of the HER3-directed antibody-drug conjugate patritumab deruxtecan for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer.
The implementation and subsequent optimization of a health information technology module within the electronic health record has allowed clinicians across a diverse health care system to identify barriers to improve discrete capture of cancer staging and design solutions to address them.
The transmembrane protein B7-H4 has emerged as an interesting therapeutic target in multiple solid tumors, with investigators mostly focusing on the development of antibody-drug conjugates aimed at the pathway.
Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.
Tucatinib, which inhibits phosphorylation of HER2/3 resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, has shown promise for patients with brain metastases as the small molecule inhibitor of HER2 can cross the blood-brain barrier.
Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.
The presence of mutated SRSF2 in knock-in mouse models of JAK2 V617F–driven myeloproliferative neoplasms reduced the rate of polycythemia and hampered hematopoietic progenitor functions.
Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.
Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival vs ibrutinib plus placebo in patients with relapsed/refractory MCL.
Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.
Golidocitinib displayed antitumor activity and an acceptable safety profile in patients with refractory/relapsed peripheral T-cell lymphoma, according to data from the pivotal phase 2 JACKPOT8 study.
Datopotamab deruxtecan resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy among patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.
Shortages of several anticancer drugs continue to negatively impact clinicians’ ability to deliver the best possible care to patients.
Significant progress has been made in terms of understanding myeloproliferative neoplasms and developing treatment strategies to combat them.
Neoadjuvant chemotherapy preceding surgery did not result in a significant difference in 5-year overall survival rates compared with concomitant chemoradiotherapy in patients with stage IB2 to IIB cervical carcinoma, according to findings from the phase 3 EORTC-55994 trial.
Adjuvant treatment with the chemotherapy doublet of pemetrexed and cisplatin did not lead to a significant improvement in overall survival compared with vinorelbine plus cisplatin in patients with stage II to IIIA nonsquamous non–small cell lung cancer.
Preliminary findings from the phase 3 BOND-003 trial showed that treatment with cretostimogene grenadenorepvec led to sustained and durable complete responses and a tolerable safety profile in patients with high-risk non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.
With multiple antibody drug conjugate options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies.
EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union for the treatment of patients with HER2-positive breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the EU.
Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity.
A biologics license application seeking the approval of obecabtagene autoleucel for the treatment of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia has been submitted to the FDA.
Patients with relapsed/refractory mantle cell lymphoma have experienced event-free survival and overall survival benefits due to advances in second-line treatment approaches over time.
Initial induction therapy with the immunomodulatory agent lenalidomide plus the anti-CD20 monoclonal antibody rituximab led to prolonged, durable responses with a manageable safety profile in patients with previously untreated mantle cell lymphoma.
The HER2-directed CAR-macrophage therapy CT-0508 displayed a tolerable safety profile and signs of antitumor activity in patients with a variety of solid tumors.
Patients with myelodysplastic syndrome harboring a TP53 mutation experienced a survival benefit with allogeneic hematopoietic cell transplantation compared with non-HCT treatment regardless of TP53 allelic status.
The European Commission has granted marketing authorization to the combination of zanubrutinib and obinutuzumab for the treatment of adult patients with relapsed/refractory follicular lymphoma following at least 2 prior lines of systemic therapy.
A possible cause of some of the cost-related delays and nonadherence to treatment that patients with cancer and cancer survivors experience could be the time and effort they are forced to spend on administrative payment tasks related to their care.
The FDA has approved the PD-L1 IHC 22C3 pharmDx diagnostic tool to aid clinicians in identifying patients with gastric or gastroesophageal junction adenocarcinoma who may be eligible for treatment with the PD-1 inhibitor pembrolizumab.
TerSera Therapeutics LLC announced that The National Comprehensive Cancer Network Head and Neck Cancers Panel recommended the GnRH agonist goserelin for patients with recurrent, unresectable, or metastatic salivary gland tumors who were not eligible for surgery or radiation therapy.
Research has continued to focus on developing novel therapies and bringing new treatments to the sarcoma treatment paradigm.
